Research progress on intestinal absorption enhancers for macromolecular drugs

Chinese Pharmaceutical Journal

Volumn 38, Issue 10, 2003, Pages 741-744

  Lin, Xiao ^a   Xu, De Sheng ^a   Feng, Yi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BUSERELIN; CARBOMER; CARBOXYMETHYLCELLULOSE; CHITOSAN; CHITOSAN DERIVATIVE; CYCLOSPORIN A; CYSTEINE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTESTINE ABSORPTION ENHANCER; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL 400; PHENOLSULFONPHTHALEIN; POLYMER; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG RELEASE; DRUG RESEARCH; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MACROMOLECULE; NONHUMAN; RAT;

EID: 0346993221     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lennemas H. Human intestinal permeability [J]. J Pharm Sci, 1998, 87(4): 403.
2. Schipper NG, Olsson S, Hoogstraate JA, et al. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement [J]. Pharm Res, 1997, 14(7): 923.
3. Koyama Y, Miyagawa T, Kawaide A, et al. Receptor-mediated absorption of high molecular weight dextrans from intestinal tract [J]. J Controlled Release 1996, 41: 171.
4. Higaki K, Yata T, Sone M, et al. Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine [J] Res Commun Mol Pathol Pharmacol, 2001, 109(3-4): 231.
5. Uchiyama T, Sugiyama T, Quan YS, et al. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoide [J]. J Pharm Pharmacol, 1999, 51(11): 1241.
6. Quan YS, Hattori K, Lundborg E, et al. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers [J]. Biol Pharm Bull, 1998, 21(6): 615.
7. Hayashi M, Sakai T, Hasegawa Y, et al. Physiological mechanism for enhancement of paracellular drug transport [J]. J Controlled Release, 1999, 62(1-2): 141.
8. Baluom M, Friedman M, Rubinstein A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations [J]. Int J Pharm, 1998, 176(1): 21.
9. Salartash K, Gonze MD, Leone BA, et al. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat [J]. J Vasc Surg, 1999, 30(3): 526.
10. Brayden D, Creed E, O'Connell A, et al. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl) amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers [J]. Pharm Res, 1997, 14(12): 1772.
11. Numata N, Takahashi K, Mizuno N, et al. Improvement of intestinal absorption of macromolecules by nitric oxide donor [J]. J Pharm Sci, 2000, 89(10): 1296.
12. + antiport: potential role of peroxynitrous acid[J]. Surgery, 1997, 122(2): 485.
13. Hovgaard L, Brondsted H. Drug delivery studies in Caco-2 monolayers IV. Absorption enhancer effects of cyclodextrins [J]. Pharm Res, 1995, 12(9): 1328.
14. Miyake K, Arima H, Irie T, et al. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats [J]. Biol Pharm Bull, 1999, 22(1): 66.
15. Sasaki I, Tozaki H, Matsumoto K, et al. Development of an oral formulation of azetirelin, a new thyrotropin-releasinghormone (TRH) analogue, using n-lauryl-beta-D-maltopyranoside as an absorption enhancer [J]. Biol Pharm Bull, 1999, 22(6): 611.
16. Gotoh S, Nakamura R, Nishiyama M, et al. Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine [J]. J Pharm Sci, 1996, 85(8): 858.
17. Uchiyama T, Yamamoto A, Hatano H, et al. Effectiveness and toxicity screening of various absorption enhancers in the large intestine: intestinal absorption of Phenol red and protein and phospholipid release from the intestinal membrane [J]. Biol Pharm Bull, 1996, 19(12): 1618.
18. Anderberg EK, Nystrom C, Artursson P. Epithelial transport of drugs in cell culture. VI: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells [J]. J Pharm Sci, 1992, 81(9): 879.
19. Schipper NG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells [J]. Pharm Res, 1996, 13 (11):1686.
20. Thanou MM, Kotze AF, Scharringhausen T, et al. Effect of degree of quatemization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers [J]. J Controlled Release, 2000, 64(1-3): 15.
21. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives [J]. Adv Drug Deliv Rev, 2001, 52(2): 117.
22. Thanou M, Nihot MT, Jansen M, et al. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo[J]. J Pharm Sci, 2001, 90(1): 38.
23. McEwan GT, Jepson MA, Hirst BH, et al. Polycation-induced enhancement of epithelial paracellular permeability is independent of tight junctional characteristics [J]. Biochim Biophys Acta, 1993, 1148(1): 51.
24. Luessen HL, de Leeuw BJ, Langemeyer MW, et al. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo [J]. Pharm Res, 1996, 13(11): 1668.
25. Thanou M, Verhoef JC, Nihot MT, et al. Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P [J]. Pharm Res, 2001, 18 (11): 1638.
26. Clausen AE, Bernkop-Schnurch A. Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs [J]. Eur J Pharm Biopharm, 2001, 51(1): 25.
27. Lueben HL, Rentel CO, Kotze AF, et al. Polycarbophil and Chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro [J]. J Controlled Release, 1997, 45(1): 15.
28. Bernkop-Schnurch A, Steininger S. Synthesis and characterisation of mucoadhesive thiolated polymers [J]. Int J Pharm, 2000, 194 (2): 239.
29. Bernkop-Schnurch A, Scholler S, Biebel RG. Development of controlled drug release systems based on polymer-cysteine conjugates [J]. J Controlled Release, 2000, 66(1): 39.
30. Clausen AE, Bernkop-Schnurch A. In vitro evaluation of the permeation enhancing effect of thiolated polycarbophil [J] J Pharm Sci, 2000, 89(10): 1253.
31. Bemkop-Schnurch A, Brandt UM, Clausen AE. Synthesis and in vitro evaluation of chitosan-cysteine conjugates [J]. Sci Pharm, 1999, 67: 196.
32. Barrett WC, DeGnore JP, Konig S, et al. Regulation of PTP1B via glutathionylation of the active site cysteine 215 [J]. Biochemistry, 1999, 38(20): 6699.